(NASDAQ: CCCC) C4 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
C4 Therapeutics's earnings in 2026 is -$119,081,000.On average, 10 Wall Street analysts forecast CCCC's earnings for 2026 to be -$129,749,023, with the lowest CCCC earnings forecast at -$181,404,408, and the highest CCCC earnings forecast at -$86,496,118. On average, 9 Wall Street analysts forecast CCCC's earnings for 2027 to be -$118,196,824, with the lowest CCCC earnings forecast at -$170,957,033, and the highest CCCC earnings forecast at -$69,196,894.
In 2028, CCCC is forecast to generate $8,402,480 in earnings, with the lowest earnings forecast at -$93,076,607 and the highest earnings forecast at $117,024,160.